Cefepime, a fourth-generation cephalosporin, stands as a crucial component in the armamentarium against a spectrum of bacterial infections [1]. Originally introduced in the 1990s, its development responded to the escalating challenge of antibiotic resistance. Unlike its predecessors, cefepime exhibits enhanced activity against Gram-negative bacteria, including Pseudomonas aeruginosa, as well as notable efficacy against Gram-positive organisms. This broad-spectrum coverage, coupled with its relatively low susceptibility to β-lactamases, renders cefepime an invaluable asset in managing severe infections, such as nosocomial pneumonia, complicated urinary tract infections, and intra-abdominal infections [2]. Its pharmacokinetic profile allows for convenient dosing, often administered intravenously for rapid and reliable therapeutic effects. Cefepime's role in clinical practice is underscored by its ability to penetrate various body tissues and fluids, including the central nervous system, making it a valuable option